PROPOFOL-II INJECTION DIN 02376865
Health Canada record
| Active ingredient(s) | PROPOFOL 10 MG |
|---|---|
| Dosage form | Emulsion |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N01AX10 PROPOFOL |
| Original market date | 11-Jun-2013 |
| Current status date | 24-Feb-2020 |
| Source | Health Canada DPD |
Establishment licence of the holder
Pfizer Canada ULC — licence 100255, currently licensed, last inspection rating C (2023-08-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PROPOFOL
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02018950 | DIPRIVAN 1% | ASPEN PHARMACARE CANADA INC. | Emulsion | PROPOFOL 10 MG | Marketed |
| 02445654 | PROPOFLO 28 | ZOETIS CANADA INC | Solution | PROPOFOL 10 MG | Marketed |
| 02559692 | PROPOFOL INJECTION | STERIMAX INC | Emulsion | PROPOFOL 10 MG | Approved |
| 02244379 | PROPOFOL INJECTION | BAXTER CORPORATION | Emulsion | PROPOFOL 10 MG | Marketed |
| 02437643 | PROPOFOL INJECTION | FRESENIUS KABI CANADA LTD | Emulsion | PROPOFOL 10 MG | Marketed |
| 02525879 | PROPOFOL INJECTION | MARCAN PHARMACEUTICALS INC | Emulsion | PROPOFOL 10 MG | Marketed |
| 02244685 | PROPOFLO | ABBOTT LABORATORIES | Emulsion | PROPOFOL 10 MG | Cancelled Post Market |
| 02468336 | PROPOFOL | BAXTER CORPORATION | Emulsion | PROPOFOL 10 MG | Cancelled Post Market |
| 02236887 | PROPOFOL INJECTION | PFIZER CANADA ULC | Emulsion | PROPOFOL 10 MG | Cancelled Post Market |
| 02241504 | PROPOFOL INJECTION | NOVOPHARM LIMITED | Emulsion | PROPOFOL 10 MG | Cancelled Post Market |
| 02242973 | PROPOFOL INJECTION | HOSPIRA HEALTHCARE ULC | Emulsion | PROPOFOL 10 MG | Cancelled Post Market |
| 02138255 | RAPINOVET | INTERVET CANADA CORP | Solution | PROPOFOL 10 MG | Cancelled Post Market |
| 02437961 | TEVA-PROPOFOL | TEVA CANADA LIMITED | Emulsion | PROPOFOL 10 MG | Dormant |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 21381 | 2018-10-02 | Abbreviated New Drug Submission (ANDS) | MERGER - BUYOUT |
| 12810 | 2011-11-30 | Supplement to an Abbreviated New Drug Submission (SANDS) | New Formulation |
International API supply for PROPOFOL
8 valid EDQM Certificates of Suitability from 8 holders. 9 active FDA Drug Master Files.
Request a quote for PROPOFOL-II INJECTION